Cognitive improvement in late-life depression treated with vortioxetine and duloxetine in an eight-week randomized controlled trial: The role of age at first onset and change in depressive symptoms

被引:5
作者
Xue, Lingfeng [1 ]
Bocharova, Mariia [1 ]
Young, Allan H. [2 ]
Aarsland, Dag [1 ]
机构
[1] Kings Coll London, Inst Psychiat Psychol & Neurosci, Ctr Hlth Brain Ageing, London SE5 8AF, England
[2] Kings Coll London, Inst Psychiat Psychol & Neurosci, Ctr Affect Disorders, London SE5 8AF, England
关键词
Late life depression; Vortioxetine; Duloxetine; Cognitive function; Age at first onset; Randomized controlled trial; SEQUENCED TREATMENT ALTERNATIVES; LU AA21004; DOUBLE-BLIND; MULTIMODAL COMPOUND; HIPPOCAMPAL VOLUMES; TREATMENT OUTCOMES; MAJOR DEPRESSION; NEUROGENESIS; POLYMORPHISMS; ASSOCIATION;
D O I
10.1016/j.jad.2024.06.003
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Age at first onset of depression as a clinical factor affecting cognitive improvement in late life depression was investigated. Methods: This is a secondary analysis of an eight-week randomized controlled trial involving 452 elderly patients treated by vortioxetine, duloxetine or placebo (1:1:1). Patients were subcategorized into early-onset (LLD-EO) and late-onset (LLD-LO) groups divided by onset age of 50. Cognitive performance was assessed by composite score of Digit Symbol Substitution Test (DSST) and the Rey Auditory Verbal Learning Test (RAVLT) tasks, while depressive symptoms were assessed by Montgomery-& Aring;sberg Depression Rating Scale (MADRS). Results: Vortioxetine and duloxetine exhibited advantages versus placebo in improving cognitive performance in the LLD-LO group, yet not in the LLD-EO group after eight weeks. Patients in the LLD-EO group showed overall advantage to placebo in depressive symptoms before endpoint (week 8) of treatment, while patients in the LLOLO group showed no advantage until endpoint. Path analysis suggested a direct effect of vortioxetine (B = 0.656, p = .036) and duloxetine (B = 0.726, p = .028) on improving cognition in the LLD-LO group, yet in all-patients treated set both medications improved cognition indirectly through changes of depressive symptoms. Limitation: Reliability of clinical history could raise caution as it was collected by subjective recall of patients. Conclusion: Age at first onset might affect cognitive improvement as well as change in depressive symptoms and its mediation towards cognitive improvement in late life depression treated with vortioxetine and duloxetine.
引用
收藏
页码:74 / 81
页数:8
相关论文
共 55 条
[1]   Mechanisms and treatment of late-life depression [J].
Alexopoulos, George S. .
TRANSLATIONAL PSYCHIATRY, 2019, 9 (1)
[2]   A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder [J].
Alvarez, Enric ;
Perez, Victor ;
Dragheim, Marianne ;
Loft, Henrik ;
Artigas, Francesc .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2012, 15 (05) :589-600
[3]  
[Anonymous], 2001, J Postgrad Med, V47, P199
[4]  
[Anonymous], 2000, DIAGN STAT MAN MENT, V4th
[5]   The role of adult neurogenesis in psychiatric and cognitive disorders [J].
Apple, Deana M. ;
Fonseca, Rene Solano ;
Kokovay, Erzsebet .
BRAIN RESEARCH, 2017, 1655 :270-276
[6]  
Association W.-W. M., 2008, 59 WMA GEN ASS SEOUL
[7]   Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder [J].
Bang-Andersen, Benny ;
Ruhland, Thomas ;
Jorgensen, Morten ;
Smith, Garrick ;
Frederiksen, Kristen ;
Jensen, Klaus Gjervig ;
Zhong, Huailing ;
Nielsen, Soren Moller ;
Hogg, Sandra ;
Mork, Arne ;
Stensbol, Tine Bryan .
JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (09) :3206-3221
[8]   Vortioxetine for Cognitive Enhancement in Major Depression: From Animal Models to Clinical Research [J].
Bennabi, Djamila ;
Haffen, Emmanuel ;
Van Waes, Vincent .
FRONTIERS IN PSYCHIATRY, 2019, 10
[9]   Depression and dementia: Cause, consequence or coincidence? [J].
Bennett, Sophia ;
Thomas, Alan J. .
MATURITAS, 2014, 79 (02) :184-190
[10]   The mood-improving actions of antidepressants do not depend on neurogenesis but are associated with neuronal remodeling [J].
Bessa, J. M. ;
Ferreira, D. ;
Melo, I. ;
Marques, F. ;
Cerqueira, J. J. ;
Palha, J. A. ;
Almeida, O. F. X. ;
Sousa, N. .
MOLECULAR PSYCHIATRY, 2009, 14 (08) :764-773